Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine.
Front Biosci (Landmark Ed). 2012 Jan 1;17(5):1816-34. doi: 10.2741/4021.
In this article we review the evolution of cancer research involving PPARgamma, including mechanisms, target genes, and clinical applications. For the last thirteen years, the effects of PPARgamma activity on tumor biology have been studied intensely. Most of this research has focused upon the potential for employing agonists of this nuclear receptor in cancer treatment. As a monotherapy such agonists have shown little success in clinical trials, while they have shown promise as components of combination treatments both in culture and in animal models. Other investigations have explored a possible role for PPARgamma as a tumor suppressor, and as an inducer of differentiation of cancer stem cells. Whereas early studies have yielded variable conclusions regarding the prevalence of PPARgamma mutations in cancer, the protein level of this receptor has been more recently identified as a significant prognostic marker. We predict that indicators of PPARgamma activity may also serve as predictive markers for tailoring treatments.
在本文中，我们回顾了涉及 PPARγ 的癌症研究的演变，包括机制、靶基因和临床应用。在过去的十三年中，PPARγ 活性对肿瘤生物学的影响一直受到深入研究。这项研究的大部分都集中在利用这种核受体的激动剂治疗癌症的潜力上。作为单一疗法，这种激动剂在临床试验中几乎没有成功，而作为组合治疗的一部分，无论是在培养物中还是在动物模型中，它们都显示出了希望。其他研究探索了 PPARγ 作为肿瘤抑制因子和诱导癌症干细胞分化的可能性。虽然早期的研究对癌症中 PPARγ 突变的普遍性得出了不同的结论，但最近发现这种受体的蛋白水平是一个重要的预后标志物。我们预测，PPARγ 活性的指标也可能作为定制治疗的预测标志物。
